Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s happening at ASCO, and what does it mean?

READ NOW

Featured Stories


ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.

ASCO Clinical Trials Companies

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.

ASCO Clinical Trials Research & Development

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

Financing Deals StartUps and SMEs

Asia Spotlight

Chinese Public Payer Data Show More New Drugs Get Faster Coverage

China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.

China Reimbursement

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Executives On The Move: Jubilant, Mithra And More

Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

Stock Watch: Defeat Is The Mother Of Reinvention

Companies that are successful do not need to change their name, therapeutic area or product focus.

Pipeline Watch: 12 Approvals And 27 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Oncorus, Orphazyme and More

Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.

Interviews

From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.

Plotting The Path For Pharma To Maintain New-Found Trust

Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.

Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'

The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.

Ionis Invests For The Future In New Technologies, Manufacturing Innovation

Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.

See All
Graphics

Executives On The Move: Jubilant, Mithra And More

Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

Pipeline Watch: 12 Approvals And 27 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Oncorus, Orphazyme and More

Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.

Pipeline Watch: 10 Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

See All
Recent Stories

China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits

AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.

ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun

In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector

New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer

While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.

ASCO 2023 – Elevation Follows In Astellas’s Slipstream

There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 antibody-drug conjugate, but no such good news for Zai Lab’s zolbetuximab challenger.

Jazz Hits High Note With Updated Zanidatamab Data In Biliary Tract Cancer At ASCO

The company said it is in talks with the US FDA for an accelerated approval filing of the HER2-directed bispecific antibody, which showed better ORR and PFS than the standard of care.

Executives On The Move: Jubilant, Mithra And More

Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.

Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi

TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.

First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

UsernamePublicRestriction

Register